TIGIT inhibitory function is mediated by binding to its ligand the poliovirus receptor (PVR, CD155), and poliovirus receptor-relate 2/Nectin-2 (PVRL2, CD112) which are present on the surface of APCs and non-hematopoietic cells including tumor cells. Here, PVR is linked to neoplasm.